Patents Assigned to Reliant Pharmaceuticals, Inc.
-
Publication number: 20090186092Abstract: A system and method for manufacturing oral osmotic drug delivery devices including the use of a mathematical model in deriving relationships between parameters used in manufacturing the devices for a desired release rate of the active drug substance contained therein. The derived relationship is then used to control the parameters so that the active substance within the device is delivered at a desired rate. Methods of administering the oral osmotic drug delivery devices are also provided. Use of a mathematical model in deriving relationships between parameters used in the drug granulation process for a desired range of percentage fines of the drug granulation substance. The derived relationship is then used to control the parameters in the drug granulation process so that the desired percentage fines are obtained in the drug granulation substance.Type: ApplicationFiled: August 20, 2008Publication date: July 23, 2009Applicant: RELIANT PHARMACEUTICALS, INC.Inventor: Hasmukh B. PATEL
-
Publication number: 20090012167Abstract: A method and composition for blood lipid therapy by administering to the subject an effective amount of a dyslipidemic agent and omega-3 fatty acids. The method utilizes a single administration or a unit dosage of a combination of dyslipidemic agent and omega-3 fatty acids for the treatment of patients with hypertriglyceridemia, hypercholesterolemia, mixed dyslipidemia, coronary heart disease (CHD), vascular disease, artherosclerotic disease and related conditions, and the prevention or reduction of cardiovascular and vascular events.Type: ApplicationFiled: September 15, 2008Publication date: January 8, 2009Applicants: RELIANT PHARMACEUTICALS, INC., PRONOVA BIOCARE ASInventors: Roelof M. L. RONGEN, George BOBOTAS, Egil BODD, Hogne VIK
-
Publication number: 20080248114Abstract: The present invention relates, generally, to oral osmotic drug delivery systems, methods of preparing same, and methods of using oral osmotic drug delivery systems to provide controlled delivery of a drug. The oral osmotic drug delivery systems include a drug layer, an osmotic layer, and an outer coating surrounding the drug layer and osmotic layer, where the outer coating includes at least one opening therein that is provided adjacent the drug layer. The composition (% fines), shape, and weight gain of the oral osmotic delivery systems may be modified in order to provide for optimized release of the drug contained therein.Type: ApplicationFiled: June 11, 2008Publication date: October 9, 2008Applicant: RELIANT PHARMACEUTICALS, INC.Inventor: Hasmukh B. PATEL
-
Patent number: 7419684Abstract: A system and method for manufacturing oral osmotic drug delivery devices including the use of a mathematical model in deriving relationships between parameters used in manufacturing the devices for a desired release rate of the active drug substance contained therein. The derived relationship is then used to control the parameters so that the active substance within the device is delivered at a desired rate. Methods of administering the oral osmotic drug delivery devices are also provided. Use of a mathematical model in deriving relationships between parameters used in the drug granulation process for a desired range of percentage fines of the drug granulation substance. The derived relationship is then used to control the parameters in the drug granulation process so that the desired percentage fines are obtained in the drug granulation substance.Type: GrantFiled: December 22, 2006Date of Patent: September 2, 2008Assignee: Reliant Pharmaceuticals, Inc.Inventor: Hasmukh B. Patel
-
Publication number: 20080085911Abstract: Methods of utilizing a combined administration or a unit dosage of a combination of an HMG-CoA inhibitor and omega-3 fatty acids for the reduction of apolipoprotein-B levels. The methods are especially useful in the treatment of patients with hypertriglyceridemia or hypercholesterolemia or mixed dyslipidemia, coronary heart disease (CHD), vascular disease, atherosclerotic disease and related conditions, and for the prevention or reduction of cardiovascular, cardiac, and vascular events.Type: ApplicationFiled: September 7, 2007Publication date: April 10, 2008Applicant: Reliant Pharmaceuticals, Inc.Inventors: Roelof M.L. Rongen, Robert A. Shalwitz, Douglas Kling, Ralph T. Doyle
-
Publication number: 20070191467Abstract: A method of lipid therapy, comprising providing a subject group having a baseline triglyceride level of 200 to 499 mg/dl and being at or near its low-density lipoprotein cholesterol (LDL-C) level goal, and reducing the triglyceride level and the non-high-density lipoprotein cholesterol (non-HDL-C) level of the subject group as compared to treatment with a 3-hydroxy-3-methyl glutaryl coenzyme A (HMG CoA) inhibitor alone, by administering to the subject group an effective amount of an HMG CoA inhibitor and a composition comprising omega-3 fatty acids.Type: ApplicationFiled: April 30, 2007Publication date: August 16, 2007Applicant: RELIANT PHARMACEUTICAL, INC.Inventors: Roelof Rongen, George Bobotas, Egil Bodd, Hogne Vik
-
Patent number: 6930119Abstract: This invention relates to new pharmaceutical compositions and methods for their preparation, and in particular it relates to taste-masked liquid compositions comprising a solution of a histamine H2-antagonist complexed with an alginate and also containing a humectant. The solution is buffered to a pH of between about 6 to 7. The inventive solution may be flavored and sweetened and preserved.Type: GrantFiled: July 17, 2002Date of Patent: August 16, 2005Assignee: Reliant Pharmaceuticals, Inc.Inventors: George Bobotas, Abdel A. Fawzy